In the latest trading session,, 1.23 million Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) shares changed hands as the company’s beta touched 0.42. With the company’s most recent per share price at $572.75 changed hands at -$38.11 or -6.24% at last look, the market valuation stands at $62.30B. REGN’s current price is a discount, trading about -111.47% off its 52-week high of $1211.20. The share price had its 52-week low at $525.99, which suggests the last value was 8.16% up since then. When we look at Regeneron Pharmaceuticals, Inc’s average trading volume, we note the 10-day average is 0.95 million shares, with the 3-month average coming to 1.01 million.
Analysts gave the Regeneron Pharmaceuticals, Inc (REGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.65. If we narrow down to specifics, the data shows that 0 out of 22 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended REGN as a Hold, 21 felt it is a Buy and 0 rated the stock as Underweight. Regeneron Pharmaceuticals, Inc’s EPS for the current quarter is expected to be 8.48.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) trade information
Instantly REGN was in red as seen in intraday trades today. With action -2.18%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -19.59%, with the 5-day performance at -2.18% in the red. However, in the 30-day time frame, Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is -10.14% down. Looking at the short shares, we see there were 2.6 million shares sold at short interest cover period of 2.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 891.5, meaning bulls need an upside of 35.75% from its recent market value. According to analyst projections, REGN’s forecast low is 695 with 1195 as the target high. To hit the forecast high, the stock’s price needs a -108.64% plunge from its current level, while the stock would need to soar -21.34% for it to hit the projected low.
Regeneron Pharmaceuticals, Inc (REGN) estimates and forecasts
Year-over-year growth is forecast to reach -0.09% down from the last financial year.
Consensus estimates given by 19 financial analysts project the company’s revenue in the current quarter to hit an average of 3.24B. 16 analysts are of the opinion that Regeneron Pharmaceuticals, Inc’s revenue for the current quarter will be 3.47B. The company’s revenue for the corresponding quarters a year ago was 3.15B and 3.55B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3.00%. The estimates for the next quarter sales put growth at -2.18%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15.74%. The 2025 estimates are for Regeneron Pharmaceuticals, Inc earnings to decrease by -14.10%, but the outlook for the next 5-year period is at 3.46% per year.
REGN Dividends
Regeneron Pharmaceuticals, Inc is expected to release its next quarterly earnings report on 2025-Feb-03.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.58% of Regeneron Pharmaceuticals, Inc shares while 91.84% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.31%. There are 91.84% institutions holding the Regeneron Pharmaceuticals, Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 9.8515% of the shares, roughly 10.65 million REGN shares worth $11.19 billion.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.32% or 8.99 million shares worth $9.45 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund . With 3.39 shares estimated at $1.93 billion under it, the former controlled 3.17% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard 500 Index Fund held about 2.66% of the shares, roughly 2.85 shares worth around $1.62 billion.
